Mutational impact of culturing human pluripotent and adult stem cells by Kuijk, Ewart et al.
Kent Academic Repository
Full text document (pdf)
Copyright & reuse
Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all
content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions 
for further reuse of content should be sought from the publisher, author or other copyright holder. 
Versions of research
The version in the Kent Academic Repository may differ from the final published version. 
Users are advised to check http://kar.kent.ac.uk for the status of the paper. Users should always cite the 
published version of record.
Enquiries
For any further enquiries regarding the licence status of this document, please contact: 
researchsupport@kent.ac.uk
If you believe this document infringes copyright then please contact the KAR admin team with the take-down 
information provided at http://kar.kent.ac.uk/contact.html
Citation for published version
Kuijk, Ewart and Jager, Myrthe and Roest, Bastiaan van der and Locati, Mauro and Hoeck, Arne
Van and Korzelius, Jerome and Janssen, Roel and Besselink, Nicolle and Boymans, Sander and
Boxtel, Ruben van and Cuppen, Edwin  (2018) Mutational impact of culturing human pluripotent
and adult stem cells.   BioRxiv (pre-print server) .       (Unpublished)
DOI
https://doi.org/10.1101/430165




Mutational impact of culturing human pluripotent and adult 
stem cells 
Ewart Kuijk1, Myrthe Jager1, Bastiaan van der Roest1, Mauro Locati1, Arne Van Hoeck1, 




1Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, 
Utrecht University, Utrecht, the Netherlands 
2Leibniz Institute on Aging – Fritz Lipmann Institute, Jena 07745, Germany 
3Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands 
Abstract 
Genetic changes acquired during in vitro culture pose a potential risk for the successful 
application of stem cells in regenerative medicine. To assess mutation accumulation risks 
induced by culturing, we determined genetic aberrations in individual human induced 
pluripotent stem cells (iPS cells) and adult stem cells (ASCs) by whole genome sequencing 
analyses. Individual iPS cells, intestinal ASCs and liver ASCs accumulated 3.5±0.5, 7.2±1.0 
and 8.4±3.6 base substitutions per population doubling, respectively. The annual in vitro 
mutation accumulation rate of ASCs adds up to ~1600 base pair substitutions, which is ~40-
fold higher than the in vivo rate of ~40 base pair substitutions per year. Mutational analysis 
revealed a distinct in vitro induced mutational signature that is irrespective of stem cell type 
and distinct from the in vivo mutational signature. This in vitro signature is characterized by C 
to A changes that have previously been linked to oxidative stress conditions. Additionally, we 
observed stem cell-specific mutational signatures and differences in transcriptional strand 
bias, indicating differential activity of DNA repair mechanisms between stem cell types in 
culture. We demonstrate that the empirically defined mutation rates, spectra, and genomic 
distribution enable risk assessment by modelling the accumulation of specific oncogenic 
mutations during typical in vitro expansion, manipulation or screening experiments using 
human stem cells. Taken together, we have here for the first time accurately quantified and 
characterized in vitro mutation accumulation in human iPS cells and ASCs in a direct 
comparison. These results provide insights for further optimization of culture conditions for 
safe in vivo utilization of these cell types for regenerative purposes. 
Introduction 
 As infinite supplies of undifferentiated and specialized cells, induced pluripotent stem 
(iPS) cells and adult stem cell (ASC)-derived organoids hold great potential in regenerative 
medicine 1. Furthermore, stem cells have become invaluable tools in pharmacology and 
toxicology for in vitro testing. Maintenance of genomic integrity in culture is a prerequisite 
for the successful application of stem cells, as unwanted mutations may influence drug 
responses and toxicology measurements or might lead to oncogenic transformation following 
transplantation. However, multiple studies have identified recurrent genomic alterations that 
originate in routinely cultured human adult and pluripotent stem cell lines 2-15. Although these 
studies suggest that the genomic integrity of stem cells is reduced in culture, the majority of 
these studies have been performed on bulk cultures with methods that have limited resolution. 
Analysis of bulk samples poses important limitations as only mutations that are shared among 
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the majority of the cells are detectable. This results in a bias towards those genomic 
alterations that confer a selective advantage upon the cells or those that occurred early in the 
culturing process. The mutational impact of the culturing process itself and the responsible 
mutational mechanisms remain as yet unclear. A better understanding of the mutational 
processes that are active in culture might enable us to improve genomic stability in culture, 
e.g. by changing the culture conditions.  
 We recently established a method to accurately identify in vivo acquired somatic 
mutations in individual stem cells at base pair resolution by combining whole genome 
sequencing (WGS) with in vitro clonal expansion. In short, stem cells are seeded as single 
cells and propagated to obtain sufficient cells for DNA isolation and subsequent whole 
genome sequencing (WGS). Bioinformatic analyses are performed that identify with high 
confidence those mutations (single nucleotide variants, indels, copy number alterations 
(CNAs), structural variants (SVs), aneuploidies) present in the original cell and filter out 
subclonal mutations that occurred after the single cell step 16. With this approach, high noise 
rates of in vitro amplification approaches are avoided and mutation loads as low as hundreds 
of mutations genome-wide can be reliably detected. The resultant genome-wide mutation 
spectra and distribution were shown to provide novel insights into the activity of specific 
mutational and DNA repair processes in adult stem cells in vivo and CRISPR/Cas9-edited 
organoids 17-19.  
 Here we have adapted this approach to systematically measure the mutational impact 
of in vitro culture on individual cells of three human stem cell types that were chosen for their 
relevance in pharmacology, toxicology and regenerative medicine: iPS cells, liver ASCs, and 
intestinal ASCs. Our study demonstrates that in vitro culture results in increased mutation 
rates and leaves a distinct but common mutational footprint related to oxidative stress in all 
three stem cell types, in addition to stem cell-specific mutational signatures. Furthermore, we 
used the measured quantitative and qualitative mutational characteristics to model genome 
wide mutation accumulation and perform genetic risk assessments associated with in vitro and 
in vivo applications of stem cells. 
Results 
Mutation accumulation in iPS cells and ASCs during culture 
 To investigate the mutational consequences of standard culture conditions on the 
genome of stem cells in an unbiased manner, we first established clonal human iPS and ASC 
lines. Each clonal line was cultured for ~2-5 months (supplementary table 1), in which 
mutations were allowed to accumulate. Subsequently, a second clonal step was performed to 
determine the acquired mutations at the individual cell level. Clonal cultures and a matched 
nonclonal reference sample were subjected to WGS (supplemental figure 1). All germline 
variants and variants that accumulated before the first clonal step were excluded based on the 
reference sample. Variants that arose in vitro after the second clonal step will be subclonal 
and could be filtered out bioinformatically based on low variant allele frequency (VAF). This 
approach allowed us to specifically measure the mutations that accumulated between the two 
clonal steps. In vitro mutation accumulation was determined in 3, 4, and 6 subclones for the 
iPS cells, liver ASCs and intestinal ASCs, respectively.  
 The total number of stem cells that is required for a particular application like e.g. cell 
therapy or drug study is achieved after a certain amount of population doublings, which is 
defined by the cell division rate and the cell death rate. Thus, from a practical perspective, 
knowledge on the mutation rates per population doubling is more informative than the number 
of mutations per time unit. Therefore, we determined the population doubling rate for all cell 
types under the same conditions that were also used for the mutation accumulation 
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experiments. We found a population doubling time of ~23h for human iPS cells which is 
approximately twice as fast as for human liver and intestinal ASCs, that have population 
doubling times of ~46h and ~44h, respectively (figure 1a).  
 The karyotypes of all clones and subclones for all three stem cell types were analyzed 
by sequencing read-depth coverage and found to be normal without any gross chromosomal 
abnormalities. CNAs were not observed for any of the subclones. Furthermore, no structural 
variants (SVs) were observed for the iPS cells. In the ASCs, however, we did observe seven 
deletions and one inversion (supplementary figure 2 and supplementary table 2). In one of the 
liver ASC subclones, a 139 bp deletion was detected and six deletions (ranging from 51 to 
97,064 bp) were observed in four of the intestinal stem cell subclones. Additionally, one of 
the intestinal subclones also contained an inversion of 4,084 bp. Four of the deletions 
involved known common fragile sites. In total, four genes overlapped with the SVs, but the 
impact on gene function is considered low as none of the SVs involved coding sequences 
(supplementary table 2).  
 In total, we detected 201 small insertions and deletions (indels) in the 13 subclones 
(supplementary table 1). After correction for the stem cell-specific growth rates, iPS cells, 
acquired 0.15 indels per genome per population doubling, which is statistically significantly 
different from the liver and intestinal ASCs with 0.36 and 0.41 indels per genome per 
population doubling respectively (ANOVA, p = 0.03; figure 1b). To assess the functional 
impact on proteins, we performed PROVEAN20 analysis, which revealed that three indels are 
in protein coding sequences, of which one in an intestinal ASC clone is predicted to be 
deleterious for protein function (supplementary table 3).  
 We identified a total of 3,888 base pair substitutions unique to the 13 subclones. Liver 
ASCs acquired 8.4±3.6 base pair substitutions per genome per population doubling. In 
intestinal ASCs, the mutation accumulation rate was similar with 7.2±1.0 base pair 
substitutions per genome per population doubling. The number of base pair substitutions was 
lower in the iPS cells than in the ASCs, with 3.5±0.5 mutations per genome per population 
doubling (ANOVA, p = 1.5E-04; figure 1c).  
 At the observed in vitro mutation rates, individual iPS cells accumulate 1,328±171 
mutations per year, intestinal ASCs accumulate 1,426±207 mutations per year, and liver stem 
cells accumulate 1,608±689 mutations per year. For the ASCs, these values are ~40-fold 
higher than the in vivo mutation accumulation rate of ~40 base pair substitutions per year 18. 
 Next, we analyzed the potential functional consequences of the observed mutations. 
Base pair substitutions were significantly depleted in genic regions for all three stem cell 
types (figure 1d). The depletion was not restricted to the protein coding sequence, but also 
included non-coding sequences, indicating that the depletion in genic regions is mainly caused 
by enhanced repair activity in genic regions and not by selection against deleterious 
mutations. The depletion was less pronounced for the iPS cells with 0.027 mutations in 
coding sequences per genome per population doubling compared to 0.041 in both ASC types 
(figure 1e). In total, we identified 14 non-synonymous mutations across all samples, 5 in the 
iPS cells, 2 in the liver ASCs, and 7 in the intestinal ASCs. For each stem cell type, this was 
found to convert in ~0.02 non-synonymous mutations per genome per population doubling 
(figure 1e and supplementary table 4). None of the non-synonymous mutations affected 
known cancer genes based on the census of human cancer genes21 or have previously been 
described to confer a selective advantage over stem cells in culture 6,14. We are therefore 
confident that the observed mutations provide an unbiased insight into mutation accumulation 
free of selection. 
 Mutations in promoter regions can affect gene activity and thereby contribute to 
disease 22,23. Mutations were depleted in the promoter regions24 of both ASC types (figure 1f). 
No depletion was observed in the promoter regions of the iPS cells. Mutations in 
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heterochromatin are generally considered harmless, because the risk that function elements 
are affected is low. In all three stem cell types, mutations were significantly enriched in 
heterochromatic laminin associated domains (LADs)(supplementary figure 3), as is the case 
for mutations that arise during reprogramming 25. Functionally relevant genomic regions thus 
appear more protected from mutation accumulation in all three stem cell types, while 
heterochromatic LADs are more susceptible to mutation accumulation.  
Mutational patterns of the SNVs 
To obtain insight into the mutational processes induced by culturing, we analyzed the 
mutation spectra in more detail. In line with our previous observation on liver stem cells26, C 
to A transversions were the predominant base substitutions in the mutational spectrum of all 
three stem cell types, encompassing nearly 30% of the base substitutions in the liver ASCs 
and over 35% of all the base substitutions in the iPS cells and the intestinal ASCs (figure 2a). 
This mutation type has been linked to reactive oxygen species (ROS) 27. In contrast with 
mutation accumulation in intestinal stem cells in vivo18, we observed only a limited relative 
contribution of C to T changes in a CpG context in intestinal stem cells in culture (figure 2a). 
The low contribution of this mutation type in in vitro-cultured intestinal stem cells indicates 
that other mutational processes are more dominant. Transcriptional strand-bias was observed 
for T to A and T to C changes in the intestinal ASCs and for T to C changes in the iPS cells 
(supplemental figure 4).  
Next, we compared the mutational profiles of the in vitro cultured stem cells to the 
COSMIC signatures17. To confirm whether the mutational processes are indeed different in 
vivo, we also included the previously described mutational profiles of in vivo accumulated 
mutations for the liver, the small intestine and the colon in this analysis 18. In line with 
previous observations, hierarchical clustering based on similarity with the COSMIC 
signatures resulted in a clear segregation between the spectra of in vivo acquired mutational 
signatures versus in vitro acquired mutations (figure 2b). Strikingly, COSMIC signature 18 
contributed to all three stem cell types (figure 2b and supplemental figure 5). Although the 
etiology of this signature is as yet unknown, signature 18 is characterized by a large 
contribution of C to A changes, in line with our observation that this is the dominant base 
substitution in all three stem cell types. Hence, in vitro mutation accumulation seems to be 
mainly determined by culture-induced high levels of oxidative stress resulting in largely 
similar mutational patterns irrespective of stem cell type.  
While COSMIC signatures 1 and 6 have a relatively large contribution to mutation 
accumulation in the intestine in vivo, their contribution to the in vitro mutation spectra is 
limited. Likewise, the contribution of signature 5 to mutation accumulation in liver stem cells 
is more prominent in vivo than in vitro. Together, these findings demonstrate that in vivo 
mutational processes only play minor roles in in vitro mutation accumulation. 
 Finally, we compared the relative contribution of all COSMIC signatures17 to the 
mutational signatures of each subclone, followed by hierarchical clustering based on these 
contributions. Cells largely clustered by stem cell type, in particular the iPS and intestinal 
stem cells, indicating that stem-cell specific mutational processes are still active in these in 
vitro cultured stem cells (figure 2c). Signature 5 contributed to the mutational profile of the 
iPS cells, but not the majority of the in vitro-cultured ASCs (figure 2c and supplemental 
figure 5). Signature 5 is characterized by transcriptional strand bias for T to C substitutions, as 
was observed for the iPS cells (supplemental figure 4). Signature 8 contributed to all small 
intestinal stem cell clones and, to a lesser extent, to the iPS cells (figure 2c and supplemental 
figure 5). Signature 8 did not contribute to 3 out of 4 liver stem cell clones. 
The mutational risk of in vitro culture 
The in vitro mutational processes may lead to the transplantation of cells carrying pathogenic 
mutations. We therefore used the empirically defined stem-cell specific mutation rates, 
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mutation spectra, and genomic distribution to model the risk of oncogenic mutations to occur 
during in vitro culture. This revealed a near linear correlation between the cumulative number 
of pathogenic mutations in oncogenes 28 as a function of the number of stem cells that are 
generated in vitro (figure 3a). In liver ASCs there is one oncogenic mutation per 2.7*106 cells, 
in intestinal ASCs one per 4.6*106 cells and in iPS cells one per 6.8 *106 cells. When 108 
intestinal ASCs are produced in vitro (a high-end estimate required for a cellular 
transplantation), the chance for at least one oncogenic mutation in the population is 
approximately 1. To place this chance in perspective we also calculated the number of 
oncogenic mutations that occur in the colon in vivo. The risk for 108 in vitro produced 
intestinal ASCs is equivalent to the risk of accumulating an oncogenic mutation in any stem 
cell in human colon in vivo in 100 days (figure 3b). Because not all possible oncogenic 
mutations are relevant for all three stem cell types we also looked at more specific mutations. 
For example, in human pluripotent stem cells dominant negative P53 mutations have been 
identified that confer a selective advantage to the cells in culture 14.  Based on our in vitro 
mutation accumulation results we predict that these mutations occur once in every ~5.7*108 
iPS cells (figure 3a). As another example, we focused on the BRAFV600E oncogenic mutation, 
which is found in ~10% of colorectal cancers29. In intestinal ASCs this mutation occurs once 
in every 1.1 *1010 stem cells (figure 3a). The chance for having a BRAFV600E mutation in the 
total cell population is 0.018, when 108 intestinal ASCs are produced in vitro. This chance is 
equivalent to the probability that a BRAFV600E mutation occurs in any colon stem cell in 112 
days of adult age (figure 3b). 
Discussion 
Many studies have described genetic abnormalities in stem cells during in vitro culture and/or 
derivation. These findings seem to contrast with the observation that stem cells have a higher 
activity of DNA repair pathways and repair damaged DNA more efficiently than 
differentiated cell types 30-32. To systematically investigate genome stability of stem cells, and 
quantify mutation accumulation, we have applied whole genome sequencing of iPS cells and 
ASCs to identify genetic aberrations that were acquired during the culturing period in between 
two clonal steps.  
 An important distinction from previous studies is that this approach enables to 
discriminate mutations that originate in culture from those that have an in vivo origin or arise 
as a result of the derivation process. Previously, we discovered that, in vivo, ASCs acquire 
~40 mutations per year 18, so for specific experimental setups the observed mutations in 
cultured cells does depend on the age of the donor. By our experimental approach we 
excluded these confounding factors and demonstrate that the in vitro mutation rates for ASCs 
are ~40-fold higher than in vivo. For tumor-derived stem cells 33, mutation rates could be even 
higher due to pre-existing increased mutation rates in tumor cells. However, the in vivo 
number should be considered in a life-long context (decades) over a large population of stem 
cells, while the in vitro number relates to the duration of culturing (weeks or months) and the 
total number of cells required.  
 Our mutational signature analyses suggest that iPS cells, liver stem cells, and 
intestinal stem cells experience distinct intrinsic mutational processes. For example, the 
intestinal stem cells showed a clear transcriptional strand-bias for T to A mutations that was 
not observed in the other stem cell types. Likewise, signature 5 contributed to all iPS cell 
subclones. In agreement with signature 5, the iPS cells showed strong transcriptional strand 
bias for T to C substitutions. These findings suggest differential activity of DNA repair 
pathways between stem cell types. Furthermore, our results show that iPS cells acquire fewer 
SNVs, indels, and SVs per population doubling than ASCs. This suggests that iPS cells 
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experience lower levels of DNA damage or have higher activity of DNA repair pathways 
multiple DNA repair pathways. Previous studies have indeed demonstrated that human 
pluripotent stem cells exhibit high activity of DNA repair pathways leading to enhanced 
capacity to repair damaged DNA 32,34. However, considering the stem-cell specific mutation 
rates, mutation spectra, and genomic distribution, iPS cells acquire only slightly fewer 
oncogenic mutations than ASCs. However, the depletion of mutations from promoter regions 
is stronger in the ASCs than in the iPS cells. Thus, human iPS cells are more protected from 
harmful coding sequence changes but more vulnerable to detrimental mutations in regulatory 
promoter regions. 
 There is a strong correlation between the number of mutations and the number of cells 
produced. As a consequence, the majority of the mutations arise during the last population 
doubling and are therefore present at very low frequencies, but also remain undetected in 
pool-based approaches. It is therefore impossible to rule out the risk that a population of cells 
that are being transplanted is devoid of any oncogenic mutation. This obviates the need to rely 
on accurate risk assessment for oncogenic mutations to occur. Our examples illustrate that  
oncogenic mutations will inevitably arise during culture as they do in vivo, but the risk for a 
specific oncogenic mutation, such as BRAFV600E, is low. We therefore think that the observed 
in vitro mutation rates should not impede their future use in regenerative medicine. However, 
to avoid unnecessary mutation accumulation we recommend to minimize the time in culture. 
 The in vitro mutation spectra of all three stem cell types are characterized by high 
numbers of C to A transversions, which are probably caused by ROS. High ROS-levels can 
cause oxidative damage to guanine, resulting in the formation of 8-oxoguanine. Incorporation 
of dAMP opposite 8-oxoguanine escapes exonucleolytic proofreading by DNA polymerases, 
generating C to A transversions during the next round of replication 27. Lowering the levels of 
ROS in culture may thus be a suitable intervention to reduce the number of C to A changes 
and the overall mutation rates, for all three stem cell types. The levels of DNA damage are 
indeed reduced when human pluripotent stem cells are cultured under low oxygen tension, but 
the effect on mutation spectrum remains to be experimentally validated 3.  
 Taken together, the experimental approach of the current study provides a suitable 
framework for studies on the effects of mutagenic environmental factors during in vitro 
culture and allows for further optimization of culture conditions to eventually reflect in vivo 
mutation rates and to establish safe in human applications of these powerful cellular tools.  
 
Material and Methods 
Stem cell culture 
All tissue culture products were from ThermoFisher scientific, unless stated otherwise. 
Integration-free human iPS cells were established from urinary cells using Sendai virus. 
Collection and culture of primary urinary cells was performed as previously described 35. In 
short, urine was collected from a healthy male volunteer and divided over 50ml tubes 
followed by centrifugation. The cell pellets were washed with PBS supplemented with 
antibiotics. The cell pellets were resuspended in primary medium containing DMEM/high 
glucose and Ham's F12 nutrient mix, supplemented with 10% (vol/vol) FBS, pen/strep, Renal 
Cell Growth Medium SingleQuots™ (Lonza) 2.5 µg ml−1 amphotericin B. The cells were 
plated onto gelatin-coated plates and incubated at 37°C in a humidified atmosphere and 5% 
CO2. Medium was refreshed daily. 96 hours after plating the medium was switched to Renal 
Cell Growth Medium supplemented with the SingleQuots™. At near confluency the cells 
were split to new gelatin coated plates using TrypLE Express. Urinary cells were 
subsequently reprogrammed by transduction with Sendai virus carrying human Klf4, Oct3/4, 
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Sox2, and C-Myc using the CytoTune™ iPS 2.0 Sendai Reprogramming Kit according to the 
manufacturer’s protocol. Approximately 10 days after transduction, individual iPS colonies 
were manually picked and cultured in E8 medium on Geltrex-coated plates 36. RNA-seq 
analysis confirmed that the iPS cells closely resembled human embryonic stem cells 
(supplemental figure 6). Clonal steps were performed by limiting dilution of a single cell 
suspension in Geltrex-coated 96-well plates. To enhance cell survival after the clonal steps of 
the iPS cells, E8 medium was supplemented with RevitaCell™. In between two clonal steps, 
the iPS cells were cultured for 3 months to accumulate mutations. After a three-month culture, 
a second clonal step was performed. The resulting clones were expanded until enough 
material was produced for whole genome sequencing. To filter out germline variants, we used 
a cell pellet from the pre-clonal bulk culture as reference sample.  
 For ASCs, we used previously established human liver and intestinal stem cell lines 
that were cultured under previously described conditions 18,26. In short, liver stem cell lines 
were cultured in Advanced DMEM/F12 with HEPES, Glutamax, and Penicillin Streptomycin. 
This medium was further supplemented with N2, B27, 1.25 mM N-Acetylcysteine (Sigma), 
10 nM gastrin (Tocris) Primocin (Invivogen), and the following growth factors: 50 ng/ml 
EGF (Peprotech), 10% RSPO1 conditioned media (homemade), 100 ng/ml FGF10 
(Peprotech), 25 ng/ml HGF (Peprotech), 10 mM Nicotinamide (Sigma), 5 uM A83.01 
(Tocris), and 10 µM FSK (Tocris). For the first 3 days after each clonal step the medium 
contained 25 ng/ml Noggin (Peprotech), 30% Wnt3a conditioned medium(homemade made 
37), 10 µM Y27632 (Abmole) and stem cell cloning recovery solution (Stemgent). Intestinal 
stem cell lines were cultured in Advanced DMEM/F12 with HEPES, Glutamax, and Penicillin 
Streptomycin. This medium was further supplemented with 50% Wnt3a conditioned medium, 
20% R-Spondin conditioned medium, B27, 1.25 mM N-Acetylcysteine, 10 mM 
Nicotinamide, Primocin, 0.5mM A83-01 (Tocris), 30mM SB202190 (Sigma), recombinant 
human Noggin (Peprotech) and 50ng/ml recombinant human EGF (Peprotech). For the first 3 
days after each clonal step the intestinal organoid medium was supplemented with 10 µM 
Y27632 
 To make clonal stem cell lines, organoids were enzymatically dissociated and the 
resulting single cell suspension was FACS-sorted to remove all doublets. The single cell 
suspension was resuspended in Matrigel (Corning) or BME (Pathclear) for intestinal stem 
cells and liver stem cells respectively and plated as a limiting dilution series. After 2-3 weeks, 
individual organoids were manually picked and mechanically fragmented and plated under 
regular culture conditions. Clonal lines were further cultured for another 53-146 days after 
which a second clonal step was performed. The resulting subclones were expanded until 
enough material was available for whole genome sequencing. Per stem cell line, a blood 
sample of the same also donor was also sequenced to enable filtering for germline variants. 
 
DNA/RNA isolation, library prep and sequencing 
DNA was isolated manually using the genomic tip 20-G kit (Qiagen) or automated using the 
Qiasymphony (Qiagen). From 200 ng genomic DNA, DNA libraries were generated for 
Illumina sequencing using standard protocols (Illumina). Libraries were sequenced 2 x 100 bp 
paired-end to 30X base coverage with the Illumina HiSeq Xten at the Hartwig Medical 
Foundation. For RNA-sequencing, human iPS cells, ES cells, liver ASCs and Intestinal ASCs 
were collected in Trizol and subjected to total RNA isolation with the QiaSymphony SP using 
the QiaSymphony RNA kit (Qiagen, 931636). Subsequently, 50 ng total RNA was used to 
prepare mRNA sequencing libraries using the Illumina Neoprep TruSeq stranded mRNA 
library prep kit (Illumina, NP-202-1001), followed by paired-end sequencing (2 x 75 bp) of 
the RNA libraries on a Nextseq500 to > 20 million reads per sample. All sequencing data has 
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been deposited at the European Genome-phenome Archive (http://www.ebi.ac.uk/ega/) under 
accession numbers EGAS00001002955, EGAS00001000881 and EGAS00001001682. 
 
Sequencing analysis 
RNA sequencing reads were mapped to the human reference genome GRCh37 with STAR 
v.2.4.2a 38 and the BAM-files were indexed using Sambamba v0.5.8. Reads were counted 
using HTSeq-count 0.6.1p1 and read counts were normalized using DESeq v1.28.0. Non-
supervised hierarchical clustering was performed using DESeq2.0 v1.20. For DNA 
sequencing read mapping and data-preprocessing was performed as previously described16. 
We determined the ‘callable regions’ of the genome for each sample that was sequenced 
based on coverage and read quality for each genomic position. Variants located in regions that 
were not callable in the reference sample were excluded from the analysis. For each sample, 
all mutations were normalized to the callable genome to determine the total number of 
mutations per whole genome (supplementary table 1). To identify all SNVs of the clonal 
cultures we used our data analysis pipeline that enables the identification of somatic SNVs 
with a confirmation rate of ~91% 18. In short, we performed basic protocols 1–2 of the 
Genome Analysis Toolkit (GATK) best practices workflow for germline single-nucleotide 
polymorphisms (SNPs) and indels in whole genomes to identify SNVs39. We subsequently 
generated a catalogue of high-quality in vitro induced SNVs using a custom Single Nucleotide 
Variant Filtering pipeline (SNVFI available at https://github.com/UMCUGenetics/SNVFI). 
The SNV call set is further filtered on the basis of several quality parameters and dbSNP 
v137.b37 40. In addition, positions that were found to be variable in at least three unrelated 
individuals were excluded as these represent either unknown SNPs or recurring sequencing 
and/or calling artefacts 16. Furthermore, events with any evidence in the reference sample 
(alternative depth >0) were excluded. Clonality of the cultures was verified by a distribution 
around 0.5 of the variant allele frequencies (VAFs) of the mutations. By filtering against all 
mutations with allele frequencies below 0.3 we excluded all mutations that arose during the 
culture period after the clonal steps. To identify all the mutations that originated in the culture 
period in between both clonal steps, the mutations identified in the second clonal culture were 
filtered for those present in the bulk and the first clonal culture. The resulting number of 
SNVs was divided by the population doublings, to obtain the point mutation rate for each 
stem cell type. Welch Two Sample t-tests were performed to determine whether the mutation 
rates differ significantly between the stem cell types. To assess the presence of the mutations 
within genes and to predict their effect, the SNVs were annotated using SnpEff 41.  
SNVs mutational profiles and genomic distributions were obtained using the R package 
MutationalPatterns 18. The COSMIC mutational signatures were downloaded from COSMIC 
website (https://cancer.sanger.ac.uk/cosmic) and their relative contribution to the total number 
of mutations was calculated for each sample. Genomic and transcriptional features were 
extracted from the hg19 assembly downloaded from the UCSC Table Browser 
(https://genome.ucsc.edu/cgi-bin/hgTables), while epigenetic status datasets were downloaded 
from the ENCODE website (https://www.encodeproject.org/) as BED files; then the SNVs 
distribution and enrichment or depletion within these regions was calculated.  
 Unfiltered indel catalogs were extracted from the germline GATK calls acquired in 
‘Single nucleotide variants’. We only considered indels within the callable autosomal genome 
of the clone, subclone, and control sample. We subsequently excluded indels that overlap with 
a SNV, indels that have a dbSNP ID and no COSMIC ID, and indels that are present on a 
blacklist of 3 unrelated samples (BED file available upon request). Furthermore, we only 
considered indels with a GATK quality score of at least 250, with a filter ‘PASS’ from 
VariantFiltration, with a coverage of at least 20x in clone, subclone, and control sample, and 
with a sample-specific genotype quality of at least 99 in clone and subclone. We subsequently 
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excluded indels with any evidence of an alternative call in the control sample and/or any of 
the other samples, with a VAF > 0.3 in the clone, and with a VAF < 0.3 in the subclone. The 
Indels were inspected manually in IGV, to excluded false positives.  
 We extrapolated the number of indels to the human autosomal genome. Subsequently 
the number of indels was divided by the number of population doublings, to obtain the indel 
mutation rate for each stem cell type. An ANOVA was performed to determine whether indel 
mutation rates differ significantly between stem cell types. To test for enrichment and 
depletion of indels within genes, we used one-sided binomial test with MutationalPatterns 42. 
Finally, we used SnpEff variant annotation to predict the effect of the mutations on the genes 
41. 
 Copy-number variants (CNVs) were called using Control-FREEC43 and filtered on the 
basis of size and evidence in the other samples. For calling structural variation we used manta 
v1.1.0 with default settings, and annotated the calls using break-point-inspector version [1] 
from commit 8d30505dfab219e367a6e5d7d3f2e6ec74877e75. We manually inspected all 
variants containing the "PASS" filter option using IGV to determine true-positive variant 
calls, and whether the structural variant accumulated in vitro. 
Modelling of in vitro mutation accumulation 
To calculate population doubling time we used the split ratios to calculate the number of cells 
we would have obtained under maximum expansion after a culture period of 44 days.  Next, 
we applied the formula  
 
D = T ln(2)/ln(Xe/Xb) 
 
where T is the incubation time in any units, Xb is the cell number at the beginning of the 
incubation time and Xe is the cell number at the end of the incubation time.  To calculate the 
number of mutations in the protein coding fraction of the genome we applied the formula:  
 
M(t) = 	0.015	·	dp	·	µ	·	N0	·	2(mt/D).G(t) 
where M(t) is the number of mutations at timepoint t, 0.015	is	the	coding	fraction	of	the	whole	genome	and	dp	is	the	degree	of	depletion	in	the	CDS,	µ	is	the	number	of	mutations	per	cell	cycle,	N(0)	is	the	number	of	initial	cells,	mt	is	the	cell	cycle	length,	and	G(t)	is	the	number	of	generations	at	timepoint	t.	For	ASCs we used a cell cycle length of ~26h as 
determined in intestinal stem cells (data not shown) and for iPS cells we applied a cell cycle 
length of ~18h44.  
We used a list of oncogenic mutations in driver genes from Tamborero et al. 28 to calculate the 
number of mutations in the coding sequence activate cancer driver genes. The probabilities P	
that mutation types (C	→	A, C	→	G, C	→	T, T	→	A, T	→	C	and T	→	G) happen in the genome can 
be derived from the mutation spectrum of the cell type.  To calculate the number of oncogenic 
mutations as a function of the number of cells, we applied the following formula: 
 
 
where Mactive is number of mutations that activate driver genes, dp is depletion in CDS, µ is 
the mutation rate, N is number of cells, PX>Y is chance on X>Y mutation based on the 
.CC-BY-NC 4.0 International licensewas not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (whichthis version posted September 29, 2018. . https://doi.org/10.1101/430165doi: bioRxiv preprint 
mutation spectrum, nX>Y is the number of positions where X>Y mutation result in oncogene 
activation and L is the length of CDS.  
To calculate the probability for an oncogenic mutation as a function of the number of cells we 




To calculate the probability for an oncogenic mutation in vivo in 108 colon stem cells as a 
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Figures 
Figure 1: In vitro mutation accumulation in iPS cells, liver stem cells, and intestinal stem cells. a, Growth 
curves for iPS cells, liver stem cells, and intestinal stem cells b, Number of indels per genome per population 
doubling, asterisks denote statistically significant differences (ANOVA) c, Number of mutations per genome per 
population doubling, asterisks denote statistically significant differences (ANOVA) d, Top panels: genomic 
distribution of the observed versus the expected amount of mutations per genome per doubling at genic regions, 
coding sequences and non-coding sequences. Error bars represent the standard deviation. Bottom panels: log2 of 
the ratio between the total number of observed mutations versus the total number of the expected amount of 
mutations at genic regions, coding sequences and non-coding sequences. Asterisks denote statistically significant 
differences between observed and expected (binomial test). e, Total number of somatic base substitutions per cell 
type (left circles) and those affecting protein-coding DNA (right circles), f, Top panels: genomic distribution of 
the observed versus the expected amount of mutations per genome per doubling at promoter and promoter 
flanking regions. Error bars represent the standard deviation. Bottom panels: log2 of the ratio between the total 
number of observed versus the total number of the expected amount of mutations at promoter and promoter 
flanking regions. Asterisks denote statistically significant differences between observed and expected. 
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Figure 2: Mutational spectrum 
and signature analysis. a, 
Relative contribution of the 
indicated base substitution types 
to the mutation spectrum. Per stem 
cell type, data are represented as 
the mean relative contribution of 
each mutation type over all 
subclones. Error bars represent the 
standard deviation. The total 
number of SNVs is indicated. b, 
Cosine similarity heatmap 
between the mutational profiles in 
the subclones and the COSMIC 
signatures, using unsupervised 
clustering of the subclones. Open 
squares indicate in vivo clones 
from Blokzijl et al. 18, closed 
squares indicate in vitro subclones 
(this study). c, Relative 
contribution of COSMIC 
signatures to the mutational 
profiles of the subclones using 
unsupervised clustering of the 
subclones. Open squares indicate 
in vivo clones from Blokzijl et al. 
18, closed squares indicate in vitro 
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Figure 3: Modelling the oncogenic mutations in in vitro cultured stem cells. a, The 
number of oncogenic mutations as a function of the number of in vitro produced cells. b, The 
probability of oncogenic mutations (x-axis) as a function of the number of in vitro produced 
ASCs (primary y-axis) and as a function of years of adult life (secondary y-axis). c, The 
probability of BRAFV600E mutations (x-axis) as a function of the number of in vitro produced 




.CC-BY-NC 4.0 International licensewas not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (whichthis version posted September 29, 2018. . https://doi.org/10.1101/430165doi: bioRxiv preprint 
Supplementary figures: 
Supplementary figure 1: Experimental set-up. Schematic overview of the experimental 
setup to determine in vitro accumulated mutations in individual human iPS cells, liver stem 
cells, and intestinal stem cells. Clonal stem cell lines were cultured for ~2-5 months during 
which mutations were allowed to accumulate. At the end of the culture period a 2nd clonal step 
was performed and the derivative subclones were expanded until enough DNA could be 
isolated for WGS analysis. A biopsy or bulk culture was used as a reference sample to 
determine and exclude all germline variants. 
 
Supplementary figure 2: In vitro accumulation of structural variation in iPS cells, liver stem cells, and 
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Supplemental figure 3: Genomic distribution. Observed versus expected amount of mutations at laminin 
associated domains. Asterisks denote significant differences between observed and expected (binomial test). 
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Supplemental figure 4: Transcriptional strand bias of in vitro accumulated mutations. Asterisks denote 
significant differences between observed and expected (binomial test). 
 
Supplemental figure 5: Relative contribution of the COSMIC signatures to the in vivo and in vitro 
mutation accumulation in stem cells. 
 
Supplemental figure 6: Heatmap and unsupervised hierarchical clustering of RNA-seq data for all genes 
for human iPS cells, human ES cells, human liver stem cells and human intestinal stem cells 
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 Supplementary tables 
Supplementary table 1: Days in culture, callable genome, number of mutations, and the number of 





















































































0.89 15 16.84 0.18 5.49 23.08 0.18 
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0.63 17 27.16 0.19 5.58 44.38 0.34 
 
 

























139 KCNK10 Intronic NA 






FHIT Intronic CFS 3B 






FHIT Intronic CFS 3B 




52 FHIT Intronic CFS 3B 






4084 NA NA NA 






WWOX Intronic CFS 16D 




51 CAMTA1 Intronic NA 




1103 NA NA NA 





















3 1 2 1 1 1 0 0 3 
Single_AA_
Change 
0 0 0 0 0 0 0 0 0 
Synonymou
s 
0 0 0 0 0 0 0 0 0 
Deletion 1 1 0 0 1 0 0 0 1 
Insertion 1 0 1 1 0 0 0 0 1 
Multiple_AA
_Change 
0 0 0 0 0 0 0 0 0 
Frameshift 1 0 1 0 0 1 0 0 1 
Nonsense 0 0 0 0 0 0 0 0 0 
Unknown 0 0 0 0 0 0 0 0 0 
.CC-BY-NC 4.0 International licensewas not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (whichthis version posted September 29, 2018. . https://doi.org/10.1101/430165doi: bioRxiv preprint 
Input_error 0 0 0 0 0 0 0 0 0 
Non_protein
_coding 
198 1 197 0 0 198 0 0 198 
Input_forma
t_error 
0 0 0 0 0 0 0 0 0 
 
Supplementary table 4: all mutations in the coding part of the genome. 
Gene mut type Subclone stem cell type 
ZMYM1 missense 1 iPS 
LAMC3 missense 1 iPS 
GYS2 missense 2 iPS 
SLC39A6 missense 2 iPS 
LDLR missense 2 iPS 
RSL24D1 missense 3 liver 
CEP135 missense 3 liver 
XDH missense 1 small intestine 
CYP11B1 missense 1 small intestine 
WDR59 missense 6 small intestine 
KIF2B missense 6 small intestine 
SPACA1 missense 4 small intestine 
LHFPL3 missense 4 small intestine 
DISP2 missense 6 small intestine 
MYH14 synonymous A3 iPS 
CRB1 synonymous B3 iPS 
BAI2 synonymous 1 liver 
SYNE1 synonymous 3 liver 
OR2G3 synonymous 1 small intestine 
SPTBN4 synonymous 2 small intestine 
FSIP2 synonymous 2 small intestine 
DNAH1 synonymous 2 small intestine 
RHOBTB1 synonymous 5 small intestine 
PKHD1L1 synonymous 6 small intestine 
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